Botanix Pharmaceuticals is listed on the

Australian Securities Exchange Australian Securities Exchange Ltd (ASX) is an Australian public company that operates Australia's primary Exchange (organized market), securities exchange, the Australian Securities Exchange (sometimes referred to outside of Australia as, or c ...

with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs.

Research

Botanix Pharmaceuticals product pipeline currently includes four programs for treatment of serious skin diseases: Dermatology * BTX 1503, for the treatment of moderate to severe acne * BTX 1702, for the treatment of rosacea * BTX 1204A, for the treatment of moderate atopic dermatitis Antimicrobial * BTX 1801, for use in a variety of antimicrobial applications

References

External links

* {{Western Australia Biotechnology companies of Australia Companies based in Perth, Western Australia Biotechnology companies established in 2002 Australian companies established in 2002 Cannabis and health